As more Antibody-Drug Conjugates head into the clinic, the next-generation of ADCs looms on the horizon. Next-gen strategies are required to engineer an effective therapeutic combining antibody, payload, linker and conjugation method while ensuring stability, targeted delivery, and limited off-target effects. The “Next-Generation Antibody-Drug Conjugates” conference explores the engineering finesse required to achieve improved therapeutics while adhering to the underlying biology that continually emerges, thus highlighting the path to more potent and efficacious molecules. Case Studies and data will be shared that reveal the ongoing efforts to engineer ADCs, move them into the clinic, and fight cancer along with potentially non-oncological indications.

Coverage will include, but is not limited to:

 

  • Developing new targets
  • ADC potency
  • Improving Therapeutic Index (TI)
  • Site-specific conjugation
  • New approaches to conjugation
  • Linker technology
  • Next-generation linker payloads
  • Novel payloads
  • Targeting delivery
  • Tumor targeting
  • Warhead design
  • Cytotoxic warheads
  • Drug-antibody ratio
  • Immune modulation
  • Mechanism of Action (MOA)
  • Emerging research
  • Half-life
  • PK/PD
  • Aggregation
  • Stability
  • Matching up warhead, linker and target
  • Limiting off-target side effects
  • Translating ADCs from pre-clinical development into the clinic 

* The program is subject to change without notice, due to unforeseen reason.